<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02220361</url>
  </required_header>
  <id_info>
    <org_study_id>JNi</org_study_id>
    <secondary_id>DAGZWCMC</secondary_id>
    <nct_id>NCT02220361</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine on Prevention of Side Effects of Hemabate</brief_title>
  <official_title>Phase 4 Study of Effects of Dexmedetomidine on Prevention of Side Effects of Hemabate in Cesarean Section Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jin Ni</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangzhou Women and Children's Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemabate is often used for gynecological patients. Hemabate is associated with many side
      effects, including a burning sensation in the stomach, nausea, vomiting, diarrhea etc. It is
      reported that dexmedetomidine reduce gastrointestinal reaction during perioperative period.
      We design this clinical trial to find if dexmedetomidine can prevent the side effects of
      hemabate in Cesarean Section patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SpO2 Change</measure>
    <time_frame>participants will be followed for the duration of surgery, an expected average of 2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>systolic blood pressure and diastolic blood pressure change</measure>
    <time_frame>participants will be followed for the duration of surgery, an expected average of 2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart rate change</measure>
    <time_frame>participants will be followed for the duration of surgery, an expected average of 2 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>nausea</measure>
    <time_frame>24 h postoperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>vomiting</measure>
    <time_frame>24h postoperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>fever</measure>
    <time_frame>24h postoperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>diarrhea</measure>
    <time_frame>24h postoperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>headache</measure>
    <time_frame>24h postoperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>elevated blood pressure</measure>
    <time_frame>24h postoperatively</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>chest congestion</measure>
    <time_frame>24h postoperatively</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Gynecological Patient</condition>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received 20 ml intravenous physiological saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>hemabate+high dose dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low dose dexmedetomidine</intervention_name>
    <description>received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.</description>
    <arm_group_label>low dose dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>high dose dexmedetomidine</intervention_name>
    <description>received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.
The infusion was completed in 30 minutes</description>
    <arm_group_label>hemabate+high dose dexmedetomidine group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        gynecological patients

        Exclusion Criteria:

          -  Neuromuscular and endocrine diseases

          -  Allergic reactions to a2-adrenergic agonist

          -  Previous abdominal surgery including prior caesarean section.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 14, 2014</study_first_submitted>
  <study_first_submitted_qc>August 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2014</study_first_posted>
  <last_update_submitted>September 28, 2014</last_update_submitted>
  <last_update_submitted_qc>September 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Guangzhou Women and Children's Medical Center</investigator_affiliation>
    <investigator_full_name>Jin Ni</investigator_full_name>
    <investigator_title>Department of Anesthesiology</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Carboprost tromethamine</mesh_term>
    <mesh_term>Carboprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

